Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722040 | 0.92 | TSHR (0.33) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL29101949 | 0.83 | DUT (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL15093996 | 0.83 | — | — | |
| SCHEMBL1876097 | 0.79 | BACE1 (0.31) | BACE1 | |
| SCHEMBL1085871 | 0.79 | MAPT (0.33) | GAABTN3A1BACE1ALDH1A1CA12 | |
| SCHEMBL6220404 | 0.79 | GAA (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL20168030 | 0.79 | TSHR (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL10012988 | 0.79 | TSHR (0.48) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL5903612 | 0.77 | TET2 (0.33) | TET2RECQLLMNAALDH1A1 | |
| SCHEMBL9163997 | 0.77 | BACE1 (0.30) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025228899-A1 | FURTHER HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025228900-A1 | ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-10-30 | — | — | US | disclosed |
| WO-2024173173-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| CN-111433196-B | Bradykinin B2 receptor antagonists and uses thereof | 法瓦里斯荷兰有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3998259-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| US-11261173-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2022-03-01 | — | — | US | disclosed |
| US-9346853-B2 | Synthesis of telaprevir and boceprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof including β-amino acids prepared via Mukaiyama aldol addition | SANDOZ AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20150183824-A1 | SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING beta-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION | SANDOZ AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183824-A1 | SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING beta-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION | SANDOZ AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| EP-1198461-A2 | METHOD OF DESIGNING TUBULIN POLYMERIZATION STABILIZERS | Cytoclonal Pharmaceutics, Inc. (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001005779-A2 | METHOD OF DESIGNING TUBULIN POLYMERIZATION STABILIZERS | CYTOCLONAL PHARMACEUTICS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183824-A1 | SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING beta-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION | MME, AGT, ACE | TSHR 3438/4885HSD17B10 2214/4885MGAM 895/4885 |
| US-11261173-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | TSHR 1138/4885HSD17B10 3783/4885MGAM 4467/4885 |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | TSHR 4429/4885HSD17B10 3429/4885MGAM 3037/4885 |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | TSHR 1283/4885HSD17B10 3789/4885MGAM 4681/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | TSHR 2713/4885HSD17B10 3628/4885MGAM 3654/4885 |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | TSHR 2272/4885HSD17B10 14/4885MGAM 336/4885 |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | TSHR 1138/4885HSD17B10 3783/4885MGAM 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.